A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer.

被引：0
|
作者：
Calvo, E
Rowinsky, EK
Tolcher, AW
Chu, QS
Beeram, M
Forero, L
Mettinger, KL
Eastham, E
Goetz, AD
Patnaik, A
机构：
[1] Canc Therapy & Res Ctr S Texas, San Antonio, TX USA
[2] SuperGen Inc, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2099
引用
下载
收藏
页码：151S / 151S
页数：1
相关论文
共 50 条
  • [1] Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
    Buckner, Jan C.
    Forouzesh, Bahram
    Erlichman, Charles
    Hidalgo, Manuel
    Boni, Joseph P.
    Dukart, Gary
    Berkenblit, Anna
    Rowinsky, Eric K.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (03) : 334 - 342
  • [2] Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
    Jan C. Buckner
    Bahram Forouzesh
    Charles Erlichman
    Manuel Hidalgo
    Joseph P. Boni
    Gary Dukart
    Anna Berkenblit
    Eric K. Rowinsky
    Investigational New Drugs, 2010, 28 : 334 - 342
  • [3] Phase I study of rubitecan and gemcitabine in patients with advanced malignancies
    Fracasso, PM
    Rader, JS
    Govindan, R
    Herzog, TJ
    Arquette, MA
    Denes, A
    Mutch, DG
    Picus, J
    Tan, BR
    Fears, CL
    Goodner, SA
    Sun, SL
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1819 - 1825
  • [4] Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer.
    Beerepoot, L.
    Rademaker-Lakhai, J.
    Witteveen, E.
    Radema, S.
    Viseren-Grul, C.
    Musib, L.
    Van Hal, J.
    Beijnen, J.
    Schellens, J.
    Voest, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 90S - 90S
  • [5] Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    Tan, Benjamin R.
    Suresh, Rama
    Lim, Kian-Huat
    Ratner, Lee
    Morton, Ashley
    Huffman, Jess
    Marquez, Samantha
    Boice, Nicolas
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    Tan, Benjamin R.
    Suresh, Rama
    Lim, Kian-Huat
    Ratner, Lee
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, Albert C.
    Tan, Benjamin R.
    Suresh, Rama
    Singh, Preet Paul
    Lim, Kian-Huat
    Morton, Ashley
    Huffman, Jess
    Marquez, Samantha
    Boice, Nicolas
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    Bhargava, P
    Marshall, JL
    Fried, K
    Williams, M
    Lefebvre, P
    Dahut, W
    Hanfelt, J
    Gehan, E
    Figuera, M
    Hawkins, MJ
    Rizvi, NA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (02) : 95 - 103
  • [9] Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
    Pankaj Bhargava
    John L. Marshall
    Karen Fried
    Marion Williams
    Patricia Lefebvre
    William Dahut
    John Hanfelt
    Edmund Gehan
    Manuela Figuera
    Michael J. Hawkins
    Naiyer A. Rizvi
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 95 - 103
  • [10] TOPOTECAN, A NEW TOPOISOMERASE-I (TOPO-I) INHIBITOR, HAS SIGNIFICANT ACTIVITY IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    BERAN, M
    KANTARJIAN, H
    OBRIEN, S
    ESTEY, E
    ANDREEFF, M
    PIERCE, S
    ROBINSON, J
    KOLLER, C
    KEATING, M
    BLOOD, 1994, 84 (10) : A151 - A151
12345